Meniere's Disease: Diagnosis, Attack Management and Long-Term Treatment

Meniere's disease (MD) is a chronic, idiopathic inner-ear disorder. Originally described by Prosper Meniere in 1861: episodic vertigo + hearing loss + tinnitus + aural fullness.

Pathophysiology: endolymphatic hydrops — excessive accumulation of endolymph in the inner ear. Endolymph is the electrolyte-rich fluid bathing the cochlea and vestibular system. Excess fluid distends Reissner's membrane and other inner-ear structures; this creates cellular dysfunction and mechanical pressure.

Causes are debated: idiopathic (most common — cause unclear), genetic predisposition (family history in 10-20%), autoimmune (autoantibodies, IgG), viral (herpes virus theory), vascular (microcirculatory disorder), allergic (food allergies as triggers), trauma, craniofacial anomaly.

Incidence: 50-200 per 100,000 (varies by population study). Most common between 30-60 years. 1.3-fold more common in women than men. Bilateral in 15-25% (usually the other ear is involved within 2-5 years).

Natural course: active phase (1-15 years) — frequent vertigo attacks, fluctuating hearing. Then a "burned out" phase (attack frequency declines, vertigo intensity drops, but hearing loss becomes permanent). Treatment aims to preserve quality of life; there is no cure. Related overview: our otology and hearing centre.

The Bárány Society and the international classification updated the diagnostic criteria in 2015. Definite and probable Meniere's categories.

Definite Meniere's: at least 2 spontaneous vertigo episodes lasting 20 min - 12 h, audiometrically documented low-mid frequency sensorineural hearing loss in the affected ear (during at least one episode), fluctuating aural symptoms (hearing, tinnitus, fullness) in the affected ear, not better explained by another diagnosis.

Probable Meniere's: 2 episodes of vertigo or imbalance lasting 20 min - 24 h, fluctuating aural symptoms, not better explained by another diagnosis. Documented audiometric loss not required.

Typical attack character: rotational vertigo developing over minutes, associated nausea/vomiting, ataxia, sweating, pallor, loss of balance. Cochlear symptoms (hearing decrease, increased tinnitus, increased fullness) before or during the attack — auras. Slow recovery over hours afterwards. Asymptomatic between attacks.

Atypical forms: Tumarkin crises (drop attacks — sudden falls without loss of consciousness) — may appear late in disease. Lermoyez syndrome — hearing paradoxically improves during the attack.

Detailed history: vertigo character (rotational — spinning, pressure — pressure, linear — pulling), duration (seconds / minutes / hours), triggers (position change, noise, salt intake), associated aural symptoms, age, family history, medications, cranial trauma.

Otoscopy: external canal and tympanic membrane assessment. Usually normal — perforation, effusion, otosclerosis excluded.

Pure-tone audiometry: foundation test. Low-frequency (250-1000 Hz) sensorineural loss is typical. Fluctuating loss in the active phase — recovers weeks after an attack.

Additional audiology: speech discrimination (word recognition — falls in Meniere's), acoustic reflex, otoacoustic emissions (OAE).

Vestibular tests: caloric (>20% paresis on the affected side is typical), video Head Impulse Test (vHIT — lateral canal function), cervical and ocular vestibular-evoked myogenic potentials (cVEMP, oVEMP — saccule and utricle function). Interpreted together.

Imaging: MRI (IAC — to rule out acoustic neuroma, MS, vascular pathology). With 3T MRI and delayed-gadolinium protocols, endolymphatic hydrops can be visualised (research area).

Laboratory: not routine; if autoimmune is suspected (young, bilateral, rapid progression) — ANA, TSH, B12, syphilis tests.

Differential diagnosis: vestibular migraine (most commonly confused — vertigo + headache, shorter attacks), benign paroxysmal positional vertigo (BPPV — seconds-long positional vertigo), vestibular neuritis (single attack lasting hours-days), labyrinthitis, acoustic neuroma, multiple sclerosis, cardiac/orthostatic causes.

An acute vertigo attack is severe and frightening — patients typically lie down and avoid moving. Treatment is symptomatic.

Position: comfortable sitting or lying. Eyes fixed on a stable point if possible. Avoid rapid head movements.

Vestibular suppressants: meclizine 25-50 mg (every 4-6 hours), dimenhydrinate 50 mg, scopolamine patch. Acutely effective — reduces nausea and vertigo intensity. Acute use only (chronic use blocks vestibular compensation).

Benzodiazepine: diazepam 2-5 mg or lorazepam 0.5-1 mg. Sedation and vestibular suppression in severe attacks. Short-term use — dependency risk.

Antiemetic: prochlorperazine 5-10 mg, ondansetron 4-8 mg (oral disintegrating tablet — for difficult swallowing). For nausea/vomiting.

Steroid rescue: in severe attacks or unresponsive cases, oral prednisone 60-80 mg/day for 5-7 days with rapid taper. Limited evidence but helpful in some patients.

Hospitalisation indications: uncontrollable vomiting, dehydration, persistent vertigo (>24 h — assess for vestibular neuritis or stroke), altered consciousness, new neurological findings.

After the attack: 24-48 hours of mild dizziness and fatigue are normal. Gentle vestibular rehab exercises (gaze fixation, slow head movements) speed recovery. Full recovery usually within 1 week. Step-by-step details: vertigo page.

Tier 1: lifestyle + medical

Low-salt diet: daily sodium below 1500-2000 mg. Reduces endolymphatic volume and pressure. Studies support efficacy. Dietitian consultation helps.

Caffeine, alcohol and smoking restriction: trigger factors. Smoking specifically worsens microcirculation.

Stress management: meditation, yoga, regular exercise, adequate sleep. Stress triggers attacks.

Thiazide diuretic: hydrochlorothiazide 25-50 mg/day or with triamterene. Thought to reduce endolymphatic pressure. Side effects: hypokalaemia (monitor potassium), dehydration.

Betahistine (Serc): 16-48 mg/day in 3 doses. Histamine H3 receptor antagonist — increases inner-ear microcirculation. Widely used in Europe. Minimal side effects. Efficacy debated (BEMED trial showed no difference vs placebo, but individual response varies).

Tier 2: intratympanic therapy

Intratympanic corticosteroid (dexamethasone 4-10 mg or methylprednisolone): in-office injection through the tympanic membrane. Series of 1-3 injections. Hearing-preserving. Vertigo control 60-80%. Can be repeated.

Tier 3: ablative therapy

Intratympanic gentamicin (titration protocol): aminoglycoside selectively damaging vestibular cells. Vertigo control 85-90%; but 20-40% risk of permanent hearing loss (titration reduces this). A good option when hearing is already poor.

Positive pressure therapy (Meniett device): a ventilation tube is placed; a home device delivers pulsed air pressure. Thought to reduce endolymphatic pressure. Some studies show efficacy.

Surgical options:

Endolymphatic sac decompression: non-ablative, conservative. Bone around the sac is removed to relieve pressure. Hearing preserved. Vertigo control 60-70%. Often tried because of low invasiveness.

Vestibular neurectomy: section of the vestibular nerve while preserving the cochlear nerve. Vertigo control 95%+, hearing preserved but balance compensation takes months. Preferred in young, healthy patients wanting hearing preserved.

Labyrinthectomy: full inner ear removal — 100% vertigo control but hearing completely lost. Last resort for advanced cases or already total hearing loss.

Meniere's is chronic but manageable. Most patients control attacks with appropriate treatment and live normally. Therapy is adjusted over years.

Dynamic treatment: in the active phase, attack severity and frequency vary. The plan should be revisited every 3-6 months. A patient diary (attack frequency, severity, triggers, diet) helps optimisation.

Vestibular rehabilitation: important after ablative therapy (gentamicin, neurectomy). Gaze stabilisation, balance and postural exercises under a physiotherapist. Compensation takes months.

Social and psychological impact: recurrent attacks can cause anxiety, depression and social isolation. Constant attack anticipation is exhausting. Cognitive-behavioural therapy (CBT) is effective. Support groups (Meniere Society) help.

Work and activity: some jobs are risky (crane operation, working at heights, professional driving). Most activities are possible between attacks. Driving: allowed during stable periods, but unpredictability requires caution. Diving is prohibited (pressure changes can trigger attacks).

Hearing aids: for permanent hearing loss after the fluctuating phase. Modern programmable digital devices tolerate Meniere's fluctuating loss well.

Bilateral disease: develops in 15-25%. Treatment decision becomes harder — ablative therapy (gentamicin) is unilateral; bilateral ablation causes dramatic balance loss. Endolymphatic sac surgery or other approaches preferred.

Natural history: active phase 1-15 years, then "burn out" — frequency declines, vertigo softens, but permanent hearing loss and balance impairment remain. The patient feels better in this phase but hearing and balance rehabilitation matter.

Outcome categories (AAO-HNS): A (no attacks), B (≥60% frequency reduction), C (20-60% reduction), D (no change), E (worse). Target A or B class. Related reading: our patient testimonials.